Introduction
The p53 gene is one of the most frequently altered genes in human cancer. This nuclear phosphoprotein is inactivated in a variety of human tumors by mutation; p53 can also be disabled through complex formation with either viral oncogene products or by binding to a cellular protein encoded by the mdm-2 oncogene (1) . Wild-type (wt)'-p53 suppresses oncogene-mediated cell transformation and decreases the tumorigenicity of human tumor cell lines. The physiological role of wt-p53 probably is to maintain the integrity of the normal genome. In response to exposure to DNA-damaging agents (gamma or ultraviolet irradiation), the level of wt-p53 protein increases and acts as a checkpoint control by blocking the cell cycle in the GI phase, which in turn results either in a delay in progress through the cell cycle to permit repair processes or in the initiation of programmed cell death (apoptosis) (2, 3) . Although the exact molecular mechanisms to explain the function of wt-p53 have not yet been elucidated, wt-p53 can both transactivate and suppress gene expression (4) . In vitro, wt-p53 protein represses the activity of several gene promotors (e.g., c-fos, c-jun, -actin, and IL-6) by interaction with the TATA binding protein (5) . By binding to p53 sequence specific DNA consensus sites, wt-p53 can transactivate the expression of GADD45, mdm-2 and WAF] (wt-p53-activated fragment) gene (6) (7) (8) .
WAFI is a recently identified gene induced in wild-type but not in mutant p53 gene-expressing cells (8) . A p53 DNAbinding site was found 2.4 kb upstream of the coding sequences of WAF-]. In vitro growth of human brain, lung, and colon tumor cells is suppressed when a WAFI expression vector is transduced into these cells. The WAF] gene is localized to human chromosome 6p2l.2 and encodes a nuclear protein of 21 kD (p2J WAFI). The same protein was simultaneously discovered as a cyclin-dependent kinase-interacting protein (CIPI) with potent GI-cyclin-dependent kinase (Cdk) inhibitory activity (9) . In normal human diploid fibroblasts, p2J WAFI/CIPI forms complexes with cyclins (A, B, D, and E classes) associated with Cdks and proliferating nuclear antigen (PCNA) (10, 11) . In SV-40 transformed cells, Cdk4 dissociates from the quaternary complex and associates with a protein of 16 kD (pl6) which inhibits Cdk4/cyclin D enzyme activity (12, 13) . Moreover, p21 WAFI/CIPl directly inhibits PCNA-dependent DNA replication in the absence of cyclin/Cdk (14) . In fibroblasts from Li-Fraumeni patients with p53 germline mutations and secondary loss of the wt-p53 allele through continuated passage, both PCNA and p2]WAF'IC'IP protein were absent and not replaced by p16 (12) . Furthermore, a cDNA isolated from senescent human fibroblasts exhibiting DNA synthesis inhibitory activity when introduced into young cycling cells, referred to as senes-lines which overexpress p53, myeloid leukemic cell lines frequently fail to express wt-p53 (18) (19) (20) . Mutations in the p53 coding sequence are found in lymphoid and myeloid tumor cell lines, aggressive non-Hodgkin's lymphomas (NHL) and in at least 25% of chronic myeloid leukemia (CML) cases in blast crisis (21) (22) (23) (24) (25) .
In this study, we examined the expression of p2l WAFI/CIPI/ SDII in neoplastic cells from patients with various hematological malignancies and in several leukemia/lymphoma cell lines. By using the HL-60 promyelocytic cells which lack p53 expression because of a large deletion of the p53 gene ( 18, 26) (10 ,ug) were size-separated by an agarose-formaldehyde gel (1% wt/ vol) and transferred to nylon membrane (Hybond-N; Amersham International, Buckinghamshire, United Kingdom). Hybridization with random-primer 32P-labeled probes ( 1-2 x 106 cpm/ml hybridization solution) was performed for 16-24 h at 42°C. Filters were washed to a final stringency of 0.25 % SSC at 65°C and exposed for 6-96 h at -70°C to XM-films (3M; Trimax, Ferrania, Italy). Some filters were deliberately overexposed with respect to the positive controls to detect low levels of mRNA. Purified inserts were used as human cDNA probes:
wt-p53 (1.1 kb, BamHI/EcoRI) from pcDNAI (27) , and p2JWAFI/CIPI/ SDII (2.1 kb, BamHI/HindIII) from pCEP (8), myeloperoxidase (MPO; PstI fragment) from pUC8 (28) , and interleukin 8 (IL-8; 0.85 kb BamHI) from p(NAP)6T3 (29) . Normal human diploid fibroblasts WI-38, known to express wt-p53 and p2] WAF/CIPI/SDII were used as positive controls ( 11) . In the half-life experiments, autoradiograms were quantified by optical scanning using the IMAGEQUANT® software (Version 3.3, Molecular Dynamics, Inc., Sunnyvale, CA) on a personal computer.
Nuclear run-on assay. Nuclear run-on assays were performed as described previously (30) with some modifications. Briefly, nuclei were prepared by lysis of HL-60 cells in 10 mM Tris/HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2, and 0.5% NP-40. 6 x 107 nuclei, suspended in 100 ul of buffer consisting of 50 mM Tris/HCl, pH 8.3, 40% glycerol, 5 mM MgCl2, and 0.1 mM EDTA, were added to 100 jl transcription buffer (20% glycerol, 100 mM KCI, 5 mM MgCl2, 1 mM each of ATP, GTP, and CTP, S mM dithiothreitol, 100 ,uCi [a-32P] UTP (400 Ci/ mmol), and 100 U RNasin). After incubation for 20 min at 30°C, the elongated transcripts were extracted and purified by the acid guanidinium thiocyanate phenol-chloroform procedure. The RNA was finally dissolved in 2 ml of hybridization buffer and hybridized to denatured plasmid DNAs (p21 WAFI/CIPI/SDIIp53 MPO, IL-8, and pUC 18) immobilized on nitrocellulose membranes (5 ,Lg/dot) at 42°C for 72 h. Membranes were washed for 20 min at 65°C in 0.2 x SSC/0.1% SDS and in 0.1 x SSC/0.1% SDS. After treatment with 10 i.g/ml RNase A at 37°C for 1 h, filters were washed in 2 x SSC for 20 min at room temperature and then exposed to x-ray film at -70°C. Western Differentiation of HL-60 cells toward monocytes but not to granulocytes is associated with an increase ofp21 WAF]ICIPI/SDII mRNA expression. Low constitutive expression of p2JWAFlICIPI/ SDI1 mRNA was observed in HL-60 cells when autoradiograms were exposed for 2 3 d despite the lack of p53 transcripts (Fig.  1) . To examine whether p21 WAFI/CIPI/SDII mRNA levels can be altered in the absence ofp53 during myeloid cell differentiation, experiments were performed with HL-60 cells induced to differentiate toward either monocytic or granulocytic cells. Both PMA and Vit D3 were used separately to induce monocyte/ macrophage differentiation, and RA and DMSO were used separately to induce granulocytic differentiation (33) . Exposure to PMA (60 ng/ml) resulted in a marked increase of p21 WAFI/CIPi/ SDI1 mRNA levels. Transcripts for p2J
WAFI/CIP1/SDII were very rapidly induced after 30-90 min of exposure to PMA, and plateau levels were reached by 9-12 h (Fig. 2) . Further experiments revealed that high levels of p2 WAFl/cIPl /SDII mRNA persisted for at least 72 h. Rehybridization of the blot with a MPO cDNA probe showed a marked decrease of MPO mRNA expression, as described previously (34) . When compared with the PMA treatment, a delayed and less pronounced increase of p21WAFI/CIPI/SDI1 mRNA expression was seen when HL-60 were cultured with Vit D3 (10-' mol/liter) (Fig. 3) . Plateau levels were reached after 72-96 h of exposure to this agent. In contrast to the monocytic pathway of differentiation, induction of HL-60 cells toward granulocytes by either RA (10-6 mol/liter, 0-96 h) or DMSO (1.25%, 0-96 h) did not result in an increase of p21 WAFI/CIPI/SDII mRNA expression.
To assess whether the increase of p21 WAFI/CIPI/SDII mRNA during phorbol-ester-induced differentiation of HL-60 cells toward the monocytic lineage is associated with an increase in p21pWAFI/CIPI/SDI protein expression, Western blot experiments were performed. As shown in Fig. 4 In addition, we determined the t112 of p21 wAFI/cIPI/sDII mRNA in cultured blast cells from two AML patients. As shown in Fig. 7 , the higher p21 WAFI/CIPI/SDII steady state transcript levels found in AML case 11 mutations. K-562 cells, which are early biphenotypic (myeloid/ erythroid) blast cells derived from a Ph+ CML patient, contain a frameshift mutation in exon 5 and do not express p53 (25, 31) . In the promyelocytic HL-60 cell line, which was established from a patient with AML M2, most of the p53 gene is deleted with some residual sequences mapping to the 5' region (26, 32) . Although these two cell lines lack p53 mRNA and protein expression, we found that both constitutively expressed 21 WAFI/CIPI/SDII mRNA. These data indicate that p21 WAFI/CIPI/ SDII is constitutively expressed in human leukemic cells independent of p53. These findings are in agreement with a very recent study showing expression of p21 WAFI/CIPI/SDII in embryonal fibroblasts from p53-deficient mice (36 
